VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Holdings in Insulet Corporation $PODD

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 79,300 shares of the medical instruments supplier's stock, valued at approximately $24,914,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.11% of Insulet at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PODD. Larson Financial Group LLC lifted its position in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares during the period. Zions Bancorporation National Association UT purchased a new position in Insulet during the 1st quarter valued at about $26,000. SouthState Corp lifted its position in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 76 shares during the period. Kozak & Associates Inc. purchased a new position in Insulet during the 2nd quarter valued at about $32,000. Finally, Trust Co. of Toledo NA OH purchased a new position in Insulet during the 2nd quarter valued at about $35,000.

Insulet Stock Up 0.7%

PODD opened at $318.59 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm has a 50 day moving average price of $326.22 and a 200-day moving average price of $302.53. Insulet Corporation has a twelve month low of $226.50 and a twelve month high of $353.50. The stock has a market capitalization of $22.43 billion, a price-to-earnings ratio of 96.84, a PEG ratio of 2.66 and a beta of 1.40.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period in the previous year, the company earned $0.55 earnings per share. The firm's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on PODD shares. Royal Bank Of Canada raised their price objective on shares of Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a research note on Friday, October 10th. Oppenheimer raised their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research note on Monday, September 8th. Canaccord Genuity Group raised their price objective on shares of Insulet from $353.00 to $399.00 and gave the company a "buy" rating in a research note on Monday, September 29th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, The Goldman Sachs Group reduced their price objective on shares of Insulet from $399.00 to $375.00 and set a "buy" rating for the company in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and an average target price of $348.05.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.